Results 131 to 140 of about 3,750,451 (195)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 2009
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
Cardiovascular events are still a major concern despite dual antiplatelet treatment with aspirin and clopidogrel. Moreover, recent developments that improved platelet inhibition were associated with increased bleeding complications, suggesting that personal dose adjustment might be needed.
Galia, Spectre, David, Varon
openaire +2 more sources
A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents
Journal of clinical pharmacology, 2019Legalization of medical cannabis has occurred in 33 states and the District of Columbia, and recreational use has increased exponentially since 2013. As a result, it is important to understand how cannabis interacts with other drugs and has potential ...
J. Greger +3 more
semanticscholar +1 more source
2018
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention. Several landmark studies for the optimal duration and dose of antiplatelet therapy in stroke prevention are discussed.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire +2 more sources
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention. Several landmark studies for the optimal duration and dose of antiplatelet therapy in stroke prevention are discussed.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire +2 more sources
Oral antiplatelet agents in cardiovascular disease.
VASA. Zeitschrift fur Gefasskrankheiten, 2019Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients.
J. Pultar +3 more
semanticscholar +1 more source
Food and Chemical Toxicology, 2018
Platelets are involved in hemostasis, inflammation, and thrombosis processes. Following a vascular damage, the endothelium releases protein factors, allowing the adhesion of subendothelium to platelets.
Harron Khan +6 more
semanticscholar +1 more source
Platelets are involved in hemostasis, inflammation, and thrombosis processes. Following a vascular damage, the endothelium releases protein factors, allowing the adhesion of subendothelium to platelets.
Harron Khan +6 more
semanticscholar +1 more source
Pharmacology of Antiplatelet Agents
Current Atherosclerosis Reports, 2013Pharmacotherapies with agents that inhibit platelet function have proven to be effective in the treatment of acute coronary syndromes, and in the prevention of complications during and after percutaneous coronary intervention. Because of multiple synergetic pathways of platelet activation and their close interplay with coagulation, current treatment ...
Kiran, Kalra +7 more
openaire +2 more sources
Antiplatelet agents in hemodialysis
Journal of Nephrology, 2016Patients affected by cardiovascular disease (CVD) are treated with antiplatelet agents (AA) and/or anticoagulant drugs, which are fundamental in the management of stroke, coronary atherosclerotic disease, peripheral vascular disease and atrial fibrillation. CVD is the most important cause of death in chronic renal failure (CRF).
Massimiliano Migliori +3 more
openaire +4 more sources
Antiplatelet Agents for Stroke Prevention
Cerebrovascular Diseases, 2000Antiplatelet agents for stroke ...
Paciaroni M, Gallai V
openaire +3 more sources
Recent Advances in Antiplatelet Agents
Current Medicinal Chemistry, 2002Platelet aggregation plays a key role in the pathogenesis of thromboembolic diseases such as myocardial infarction, stroke, unstable angina and peripheral artery disease. Until recently, aspirin was the only antiplatelet agent available to prevent or treat these events.
Dogné, Jean-Michel +5 more
openaire +3 more sources